US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

IDEAYA Biosciences

24.75

+0.42001.73%

Post-market: 24.750.00000.00%17:54 EDT

Volume:1.09M

Turnover:27.06M

Market Cap:2.17B

PE:-6.54

High:25.11

Open:24.35

Low:24.18

Close:24.33

52wk High:40.74

52wk Low:13.45

Shares:87.64M

Float Shares:82.44M

Volume Ratio:1.26

T/O Rate:1.32%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.7869

EPS(LYR):-3.3605

ROE:-35.09%

ROA:-23.84%

PB:2.26

PE(LYR):-7.37

Loading ...

Overview Company News Filings

IDEAYA Biosciences Is Maintained at Overweight by JP Morgan

RBC Capital Reaffirms Their Buy Rating on IDEAYA Biosciences (IDYA)

IDEAYA Gets FDA Clearance to Initiate Clinical Trial of Antibody Drug Conjugate Program in Solid Tumors

MT Newswires Live

IDEAYA Biosciences Posts Q1 Net Loss; Cash Runway Extended Through 2029

MT Newswires Live

IDEAYA Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

BRIEF-IDEAYA Biosciences Announces US FDA IND-Clearance For IDE849, A Potential First-In-Class DLL3 TOP1 ADC, For A Phase 1 Study In Solid Tumors

IDEAYA Biosciences Q1 EPS $(0.82) Misses $(0.67) Estimate

Earnings Flash (IDYA) IDEAYA Biosciences Posts Q1 Net Loss $0.82, vs. FactSet Est of $0.66 Loss

MT Newswires Live

IDEAYA Biosciences Reports Q1 2025 Results: Net Loss Down to $72.2M, Increased G&A Expenses Amid Pipeline Support

Press Release: IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events

BRIEF-Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences’ Trial Expansion and Regulatory Uncertainties Lead to Hold Rating

Mizuho Securities Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)

Ideaya trial design consisent with guidance, says Oppenheimer

Ideaya Biosciences Completes Phase 3 Trial Design Meetings With FDA; Shares Up Pre-Bell

MT Newswires Live

BRIEF-Ideaya Biosciences Announces Successful FDA Type D Meeting for Darovasertib

IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma

Ideaya Biosciences Begins Phase 1/2 Expansion in Urothelial Cancer Treatment Trial in Combination With Gilead's Trodelvy

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IDYA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IDYA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDYA\",,,,,undefined,":{"symbol":"IDYA","market":"US","secType":"STK","nameCN":"IDEAYA Biosciences","latestPrice":24.75,"timestamp":1755547200000,"preClose":24.33,"halted":0,"volume":1089244,"hourTrading":{"tag":"盘后","latestPrice":24.75,"preClose":24.75,"latestTime":"17:54 EDT","volume":23549,"amount":582841.59,"timestamp":1755554093132},"delay":0,"floatShares":82438334,"shares":87643686,"eps":-3.786934,"marketStatus":"Not Yet Opened","change":0.42,"latestTime":"08-18 16:00:00 EDT","open":24.35,"high":25.1135,"low":24.18,"amount":27058356.79404,"amplitude":0.038368,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.786934,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1755590400000},"marketStatusCode":0,"adr":0,"listingDate":1558584000000,"exchange":"NASDAQ","adjPreClose":24.33,"preHourTrading":{"tag":"盘前","latestPrice":24.2,"preClose":24.33,"latestTime":"09:01 EDT","volume":14,"amount":339.80001999999996,"timestamp":1755522103290},"postHourTrading":{"tag":"盘后","latestPrice":24.75,"preClose":24.75,"latestTime":"17:54 EDT","volume":23549,"amount":582841.59,"timestamp":1755554093132},"volumeRatio":1.264312,"impliedVol":0.3919,"impliedVolPercentile":0.26},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDYA\",,,,,undefined,":{"symbol":"IDYA","floatShares":82438334,"roa":"-23.84%","roe":"-35.09%","lyrEps":-3.360473,"volumeRatio":1.264312,"shares":87643686,"dividePrice":0,"high":25.1135,"amplitude":0.038368,"preClose":24.33,"low":24.18,"week52Low":13.45,"pbRate":"2.26","psRate":"309.88","week52High":40.74,"institutionHeld":0,"latestPrice":24.75,"eps":-3.786934,"divideRate":0,"volume":1089244,"delay":0,"ttmEps":-3.786934,"open":24.35,"prevYearClose":25.7,"prevWeekClose":24.33,"prevMonthClose":24.35,"prevQuarterClose":21.02,"fiveDayClose":22.84,"twentyDayClose":21.81,"sixtyDayClose":19.15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IDYA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-05","symbol":"IDYA","fiscalQuarterEnding":"2025/06","expectedEps":-0.85,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754366400000,"reportTimeType":"pre","actualEps":-0.88},{"market":"US","date":"2025-05-06","symbol":"IDYA","fiscalQuarterEnding":"2025/03","expectedEps":-0.75,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746504000000,"reportTimeType":"pre","actualEps":-0.82},{"market":"US","date":"2025-02-13","symbol":"IDYA","fiscalQuarterEnding":"2024/12","expectedEps":-0.67,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1739422800000,"reportTimeType":"pre","actualEps":-1.49},{"market":"US","date":"2024-11-04","symbol":"IDYA","fiscalQuarterEnding":"2024/09","expectedEps":-0.67,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730696400000,"reportTimeType":"pre","actualEps":-0.6},{"market":"US","date":"2024-08-06","symbol":"IDYA","fiscalQuarterEnding":"2024/06","expectedEps":-0.55,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1722916800000,"reportTimeType":"pre","actualEps":-0.68}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IDYA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IDYA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.375,"buy":0.5,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":16,"updateTime":1753243200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IDYA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IDYA","date":"2025-08-15","current":-6.437202,"percent":0.904878,"low":-34.624829,"twenty":-22.797965,"median":-16.087775,"eighty":-8.47506,"high":-4.624403,"avg":-16.421326,"sd":7.619353,"marketCap":2135876627},"quantilePoints":[{"date":"2020-08-21","current":-7.048659,"twenty":-5.640772,"median":-3.816589,"eighty":-3.055637,"marketCap":325535262},{"date":"2020-08-28","current":-7.325077,"twenty":-5.676643,"median":-3.829155,"eighty":-3.074854,"marketCap":338301351},{"date":"2020-09-04","current":-7.36277,"twenty":-5.888584,"median":-3.904381,"eighty":-3.091768,"marketCap":340042181},{"date":"2020-09-11","current":-7.720857,"twenty":-6.055967,"median":-3.919034,"eighty":-3.105142,"marketCap":356580069},{"date":"2020-09-18","current":-8.273693,"twenty":-6.231062,"median":-3.963154,"eighty":-3.120016,"marketCap":382112246},{"date":"2020-09-25","current":-7.30623,"twenty":-7.042906,"median":-3.999405,"eighty":-3.123017,"marketCap":337430935},{"date":"2020-10-02","current":-8.154331,"twenty":-7.144679,"median":-4.012859,"eighty":-3.134459,"marketCap":376599617},{"date":"2020-10-09","current":-8.845376,"twenty":-7.233135,"median":-4.068307,"eighty":-3.171904,"marketCap":408514839},{"date":"2020-10-16","current":-8.418184,"twenty":-7.259802,"median":-4.104763,"eighty":-3.188239,"marketCap":388785429},{"date":"2020-10-23","current":-8.022404,"twenty":-7.318795,"median":-4.119255,"eighty":-3.202593,"marketCap":370506711},{"date":"2020-10-30","current":-7.64547,"twenty":-7.366539,"median":-4.130975,"eighty":-3.208643,"marketCap":353098408},{"date":"2020-11-06","current":-8.323951,"twenty":-7.428106,"median":-4.172274,"eighty":-3.213223,"marketCap":384433353},{"date":"2020-11-13","current":-9.670314,"twenty":-7.513606,"median":-4.199125,"eighty":-3.214735,"marketCap":388176055},{"date":"2020-11-20","current":-9.0623,"twenty":-7.619934,"median":-4.22379,"eighty":-3.237383,"marketCap":363769776},{"date":"2020-11-27","current":-9.815079,"twenty":-7.650496,"median":-4.270265,"eighty":-3.257424,"marketCap":393987074},{"date":"2020-12-04","current":-11.291683,"twenty":-7.758551,"median":-4.310957,"eighty":-3.268757,"marketCap":453259466},{"date":"2020-12-11","current":-10.30728,"twenty":-7.820117,"median":-4.318821,"eighty":-3.286417,"marketCap":413744538},{"date":"2020-12-18","current":-9.453166,"twenty":-7.919802,"median":-4.333623,"eighty":-3.310899,"marketCap":379459527},{"date":"2020-12-24","current":-9.337354,"twenty":-8.007327,"median":-4.345911,"eighty":-3.319882,"marketCap":374810712},{"date":"2020-12-31","current":-10.133562,"twenty":-8.091015,"median":-4.369631,"eighty":-3.320843,"marketCap":406771316},{"date":"2021-01-08","current":-10.126324,"twenty":-8.123554,"median":-4.38073,"eighty":-3.326128,"marketCap":406480765},{"date":"2021-01-15","current":-12.196466,"twenty":-8.150562,"median":-4.396081,"eighty":-3.333257,"marketCap":489578333},{"date":"2021-01-22","current":-13.318396,"twenty":-8.217153,"median":-4.425522,"eighty":-3.338699,"marketCap":534613729},{"date":"2021-01-29","current":-12.724859,"twenty":-8.273693,"median":-4.46871,"eighty":-3.3391,"marketCap":510788552},{"date":"2021-02-05","current":-13.933648,"twenty":-8.323951,"median":-4.508424,"eighty":-3.363122,"marketCap":559310559},{"date":"2021-02-12","current":-13.687547,"twenty":-8.361644,"median":-4.550006,"eighty":-3.367926,"marketCap":549431827},{"date":"2021-02-19","current":-12.999913,"twenty":-8.520656,"median":-4.585646,"eighty":-3.370227,"marketCap":521829488},{"date":"2021-02-26","current":-13.803359,"twenty":-8.627473,"median":-4.598275,"eighty":-3.372345,"marketCap":554080642},{"date":"2021-03-05","current":-14.33899,"twenty":-8.66338,"median":-4.631301,"eighty":-3.402009,"marketCap":575581412},{"date":"2021-03-12","current":-16.611804,"twenty":-8.7798,"median":-4.691605,"eighty":-3.410799,"marketCap":666814407},{"date":"2021-03-19","current":-16.343988,"twenty":-8.84035,"median":-4.717677,"eighty":-3.415564,"marketCap":656064022},{"date":"2021-03-26","current":-21.126111,"twenty":-8.941508,"median":-4.791351,"eighty":-3.418925,"marketCap":728745203},{"date":"2021-04-01","current":-22.285243,"twenty":-9.163635,"median":-4.928537,"eighty":-3.41949,"marketCap":768729453},{"date":"2021-04-09","current":-18.564804,"twenty":-9.293924,"median":-5.059353,"eighty":-3.428909,"marketCap":640392909},{"date":"2021-04-16","current":-17.396324,"twenty":-9.505281,"median":-5.10129,"eighty":-3.441013,"marketCap":600086205},{"date":"2021-04-23","current":-19.003246,"twenty":-9.670314,"median":-5.186016,"eighty":-3.447944,"marketCap":655516972},{"date":"2021-04-30","current":-19.594416,"twenty":-9.739801,"median":-5.226626,"eighty":-3.452635,"marketCap":675909371},{"date":"2021-05-07","current":-18.288121,"twenty":-9.832451,"median":-5.324735,"eighty":-3.459277,"marketCap":630848747},{"date":"2021-05-14","current":-20.393803,"twenty":-10.104609,"median":-5.514956,"eighty":-3.464141,"marketCap":641854163},{"date":"2021-05-21","current":-21.240496,"twenty":-10.279775,"median":-5.63553,"eighty":-3.465219,"marketCap":668502132},{"date":"2021-05-28","current":-21.062795,"twenty":-10.625764,"median":-5.656499,"eighty":-3.474365,"marketCap":662909349},{"date":"2021-06-04","current":-20.989624,"twenty":-11.26273,"median":-5.676643,"eighty":-3.484294,"marketCap":660606438},{"date":"2021-06-11","current":-21.836317,"twenty":-12.053148,"median":-5.777074,"eighty":-3.496371,"marketCap":687254407},{"date":"2021-06-18","current":-23.717857,"twenty":-12.533769,"median":-5.971041,"eighty":-3.508471,"marketCap":746472115},{"date":"2021-06-25","current":-22.484403,"twenty":-12.898577,"median":-6.065403,"eighty":-3.513532,"marketCap":707651617},{"date":"2021-07-02","current":-23.059318,"twenty":-13.144678,"median":-6.217431,"eighty":-3.51557,"marketCap":725745917},{"date":"2021-07-09","current":-21.049231,"twenty":-13.370511,"median":-6.264612,"eighty":-3.517045,"marketCap":662482433},{"date":"2021-07-16","current":-22.691914,"twenty":-13.607926,"median":-7.020167,"eighty":-3.52146,"marketCap":714182615},{"date":"2021-07-23","current":-26.682771,"twenty":-13.783092,"median":-7.08007,"eighty":-3.524544,"marketCap":839786849},{"date":"2021-07-30","current":-29.809753,"twenty":-14.04946,"median":-7.153433,"eighty":-3.531687,"marketCap":938202363},{"date":"2021-08-06","current":-28.191509,"twenty":-14.587986,"median":-7.224561,"eighty":-3.533947,"marketCap":887271377},{"date":"2021-08-13","current":-29.97068,"twenty":-15.154018,"median":-7.242857,"eighty":-3.537369,"marketCap":899989535},{"date":"2021-08-20","current":-30.290333,"twenty":-16.287529,"median":-7.254477,"eighty":-3.541434,"marketCap":909588400},{"date":"2021-08-27","current":-29.305801,"twenty":-16.592186,"median":-7.303089,"eighty":-3.542962,"marketCap":880023897},{"date":"2021-09-03","current":-31.722379,"twenty":-16.958969,"median":-7.318795,"eighty":-3.549073,"marketCap":952591312},{"date":"2021-09-10","current":-33.985523,"twenty":-17.480455,"median":-7.331359,"eighty":-3.549073,"marketCap":1020551273},{"date":"2021-09-17","current":-34.343535,"twenty":-18.002071,"median":-7.384758,"eighty":-3.550496,"marketCap":1031302001},{"date":"2021-09-24","current":-32.451188,"twenty":-18.564804,"median":-7.425593,"eighty":-3.554316,"marketCap":974476724},{"date":"2021-10-01","current":-32.655766,"twenty":-19.003246,"median":-7.482701,"eighty":-3.556676,"marketCap":980619997},{"date":"2021-10-08","current":-32.70691,"twenty":-19.603951,"median":-7.576366,"eighty":-3.556676,"marketCap":982155815},{"date":"2021-10-15","current":-29.57431,"twenty":-19.948284,"median":-7.607522,"eighty":-3.556676,"marketCap":888086943},{"date":"2021-10-22","current":-29.305801,"twenty":-20.299726,"median":-7.64547,"eighty":-3.561126,"marketCap":880023897},{"date":"2021-10-29","current":-27.413454,"twenty":-20.498333,"median":-7.666222,"eighty":-3.5648,"marketCap":823198619},{"date":"2021-11-05","current":-30.149685,"twenty":-20.989624,"median":-7.758551,"eighty":-3.569714,"marketCap":905364899},{"date":"2021-11-12","current":-29.446448,"twenty":-21.062795,"median":-7.793103,"eighty":-3.570043,"marketCap":884247397},{"date":"2021-11-19","current":-24.362497,"twenty":-21.240496,"median":-7.827655,"eighty":-3.571919,"marketCap":893738217},{"date":"2021-11-26","current":-24.981527,"twenty":-21.39159,"median":-7.890477,"eighty":-3.574612,"marketCap":916447328},{"date":"2021-12-03","current":-23.145422,"twenty":-21.857223,"median":-7.96045,"eighty":-3.584136,"marketCap":849089797},{"date":"2021-12-10","current":-22.914597,"twenty":-22.068374,"median":-8.022404,"eighty":-3.586999,"marketCap":840621993},{"date":"2021-12-17","current":-22.841153,"twenty":-22.307678,"median":-8.080851,"eighty":-3.590242,"marketCap":837927691},{"date":"2021-12-23","current":-24.519878,"twenty":-22.478131,"median":-8.112599,"eighty":-3.600896,"marketCap":899511720},{"date":"2021-12-31","current":-24.803163,"twenty":-22.661484,"median":-8.124771,"eighty":-3.607486,"marketCap":909904025},{"date":"2022-01-07","current":-18.854181,"twenty":-22.696715,"median":-8.133171,"eighty":-3.607884,"marketCap":691665623},{"date":"2022-01-14","current":-18.6968,"twenty":-22.661484,"median":-8.166895,"eighty":-3.6108,"marketCap":685892120},{"date":"2022-01-21","current":-16.01084,"twenty":-22.62885,"median":-8.217153,"eighty":-3.61443,"marketCap":587357674},{"date":"2022-01-28","current":-16.304617,"twenty":-22.589226,"median":-8.232117,"eighty":-3.61955,"marketCap":598134879},{"date":"2022-02-04","current":-16.336093,"twenty":-22.528306,"median":-8.279975,"eighty":-3.626979,"marketCap":599289580},{"date":"2022-02-11","current":-15.95838,"twenty":-22.480222,"median":-8.317669,"eighty":-3.641021,"marketCap":585433173},{"date":"2022-02-18","current":-14.290147,"twenty":-22.452959,"median":-8.349952,"eighty":-3.663377,"marketCap":524234045},{"date":"2022-02-25","current":-14.300639,"twenty":-22.416661,"median":-8.361644,"eighty":-3.680345,"marketCap":524618945},{"date":"2022-03-04","current":-12.663882,"twenty":-22.374982,"median":-8.467308,"eighty":-3.689682,"marketCap":464574517},{"date":"2022-03-11","current":-13.4298,"twenty":-22.27281,"median":-8.578381,"eighty":-3.700816,"marketCap":492672230},{"date":"2022-03-18","current":-9.803903,"twenty":-22.210534,"median":-8.63295,"eighty":-3.710538,"marketCap":487861813},{"date":"2022-03-25","current":-8.880178,"twenty":-22.137363,"median":-8.648165,"eighty":-3.728362,"marketCap":441895419},{"date":"2022-04-01","current":-8.849128,"twenty":-22.038758,"median":-8.676953,"eighty":-3.732947,"marketCap":440350330},{"date":"2022-04-08","current":-8.771505,"twenty":-22.005987,"median":-8.686118,"eighty":-3.735526,"marketCap":436487608},{"date":"2022-04-14","current":-8.39891,"twenty":-21.980806,"median":-8.678356,"eighty":-3.739591,"marketCap":417946542},{"date":"2022-04-22","current":-8.297999,"twenty":-21.967416,"median":-8.654251,"eighty":-3.742674,"marketCap":412925003},{"date":"2022-04-29","current":-7.445176,"twenty":-21.940847,"median":-8.644345,"eighty":-3.747479,"marketCap":370486844},{"date":"2022-05-06","current":-7.080292,"twenty":-21.836317,"median":-8.631683,"eighty":-3.752283,"marketCap":352329512},{"date":"2022-05-13","current":-7.388684,"twenty":-21.606351,"median":-8.578381,"eighty":-3.771501,"marketCap":404559983},{"date":"2022-05-20","current":-7.762705,"twenty":-21.554086,"median":-8.467308,"eighty":-3.779737,"marketCap":425039142},{"date":"2022-05-27","current":-7.621565,"twenty":-21.406546,"median":-8.392554,"eighty":-3.780239,"marketCap":417311157},{"date":"2022-06-03","current":-8.397835,"twenty":-21.39159,"median":-8.36786,"eighty":-3.788369,"marketCap":459815071},{"date":"2022-06-10","current":-8.037928,"twenty":-21.387041,"median":-8.380207,"eighty":-3.794466,"marketCap":440108711},{"date":"2022-06-17","current":-8.729514,"twenty":-21.336664,"median":-8.392554,"eighty":-3.799547,"marketCap":477975835},{"date":"2022-06-24","current":-9.795122,"twenty":-21.273946,"median":-8.39891,"eighty":-3.80666,"marketCap":536322117},{"date":"2022-07-01","current":-10.10563,"twenty":-21.225131,"median":-8.471248,"eighty":-3.810725,"marketCap":553323683},{"date":"2022-07-08","current":-10.888958,"twenty":-21.198073,"median":-8.557964,"eighty":-3.815416,"marketCap":596213996},{"date":"2022-07-15","current":-10.938357,"twenty":-21.154154,"median":-8.623821,"eighty":-3.823859,"marketCap":598918791},{"date":"2022-07-22","current":-10.50788,"twenty":-21.113328,"median":-8.640812,"eighty":-3.827243,"marketCap":575348438},{"date":"2022-07-29","current":-10.529051,"twenty":-21.08161,"median":-8.648165,"eighty":-3.852269,"marketCap":576507636},{"date":"2022-08-05","current":-11.107725,"twenty":-21.062795,"median":-8.674304,"eighty":-3.89073,"marketCap":608192372},{"date":"2022-08-12","current":-11.044212,"twenty":-21.057369,"median":-8.686118,"eighty":-3.902788,"marketCap":604714779},{"date":"2022-08-19","current":-6.087169,"twenty":-21.027635,"median":-8.674304,"eighty":-3.912344,"marketCap":400919180},{"date":"2022-08-26","current":-5.735068,"twenty":-20.992994,"median":-8.648165,"eighty":-3.917696,"marketCap":377728757},{"date":"2022-09-02","current":-5.597808,"twenty":-20.953825,"median":-8.640812,"eighty":-3.930533,"marketCap":368688422},{"date":"2022-09-09","current":-5.520226,"twenty":-20.872033,"median":-8.630797,"eighty":-3.94283,"marketCap":363578668},{"date":"2022-09-16","current":-7.849101,"twenty":-20.73156,"median":-8.578381,"eighty":-3.96417,"marketCap":516965327},{"date":"2022-09-23","current":-8.510226,"twenty":-20.611725,"median":-8.513329,"eighty":-3.972574,"marketCap":560509001},{"date":"2022-09-30","current":-10.493601,"twenty":-20.565232,"median":-8.578381,"eighty":-3.993719,"marketCap":691140025},{"date":"2022-10-07","current":-10.198204,"twenty":-20.477427,"median":-8.630797,"eighty":-4.008882,"marketCap":671684341},{"date":"2022-10-14","current":-10.950762,"twenty":-20.387531,"median":-8.642079,"eighty":-4.009677,"marketCap":721250013},{"date":"2022-10-21","current":-11.562654,"twenty":-20.357199,"median":-8.654251,"eighty":-4.014693,"marketCap":761551073},{"date":"2022-10-28","current":-11.956516,"twenty":-20.32892,"median":-8.675551,"eighty":-4.030286,"marketCap":787491986},{"date":"2022-11-04","current":-12.005748,"twenty":-20.283001,"median":-8.686118,"eighty":-4.065307,"marketCap":790734600},{"date":"2022-11-11","current":-15.768029,"twenty":-20.180562,"median":-8.713449,"eighty":-4.079563,"marketCap":830439027},{"date":"2022-11-18","current":-16.115182,"twenty":-20.035419,"median":-8.773737,"eighty":-4.104617,"marketCap":848722157},{"date":"2022-11-25","current":-16.060368,"twenty":-20.023491,"median":-8.779267,"eighty":-4.104763,"marketCap":845835347},{"date":"2022-12-02","current":-16.425792,"twenty":-19.948284,"median":-8.800314,"eighty":-4.104763,"marketCap":865080747},{"date":"2022-12-09","current":-15.384334,"twenty":-19.937676,"median":-8.842235,"eighty":-4.115583,"marketCap":810231356},{"date":"2022-12-16","current":-15.39347,"twenty":-19.766046,"median":-8.880178,"eighty":-4.122926,"marketCap":810712491},{"date":"2022-12-23","current":-15.548775,"twenty":-19.620281,"median":-8.920409,"eighty":-4.130826,"marketCap":818891787},{"date":"2022-12-30","current":-16.599368,"twenty":-19.607217,"median":-8.936255,"eighty":-4.130945,"marketCap":874222313},{"date":"2023-01-06","current":-15.777165,"twenty":-19.59823,"median":-8.94733,"eighty":-4.146129,"marketCap":830920162},{"date":"2023-01-13","current":-17.101825,"twenty":-19.554345,"median":-9.043188,"eighty":-4.162328,"marketCap":900684738},{"date":"2023-01-20","current":-16.106046,"twenty":-19.478065,"median":-9.066475,"eighty":-4.171098,"marketCap":848241022},{"date":"2023-01-27","current":-15.420877,"twenty":-19.243528,"median":-9.155743,"eighty":-4.18158,"marketCap":812155896},{"date":"2023-02-03","current":-16.042097,"twenty":-18.988351,"median":-9.163635,"eighty":-4.19168,"marketCap":844873077},{"date":"2023-02-10","current":-16.416656,"twenty":-18.921278,"median":-9.21308,"eighty":-4.201222,"marketCap":864599612},{"date":"2023-02-17","current":-16.16086,"twenty":-18.818457,"median":-9.237619,"eighty":-4.208561,"marketCap":851127832},{"date":"2023-02-24","current":-15.567046,"twenty":-18.755454,"median":-9.279961,"eighty":-4.218427,"marketCap":819854057},{"date":"2023-03-03","current":-15.7863,"twenty":-18.713587,"median":-9.288903,"eighty":-4.239786,"marketCap":831401297},{"date":"2023-03-10","current":-12.695923,"twenty":-18.685623,"median":-9.337354,"eighty":-4.268913,"marketCap":744679346},{"date":"2023-03-17","current":-12.365944,"twenty":-18.625694,"median":-9.47488,"eighty":-4.277714,"marketCap":725324457},{"date":"2023-03-24","current":-11.450254,"twenty":-18.520909,"median":-9.51831,"eighty":-4.30099,"marketCap":671614641},{"date":"2023-03-31","current":-11.326512,"twenty":-18.333889,"median":-9.637448,"eighty":-4.31253,"marketCap":664356558},{"date":"2023-04-06","current":-11.343011,"twenty":-18.288121,"median":-9.673933,"eighty":-4.318821,"marketCap":665324302},{"date":"2023-04-14","current":-11.433755,"twenty":-18.224659,"median":-9.699267,"eighty":-4.318821,"marketCap":670646896},{"date":"2023-04-21","current":-12.012005,"twenty":-18.140723,"median":-9.745723,"eighty":-4.318821,"marketCap":704564136},{"date":"2023-04-28","current":-17.665967,"twenty":-18.140723,"median":-9.757173,"eighty":-4.324014,"marketCap":1036197283},{"date":"2023-05-05","current":-18.5444,"twenty":-18.345331,"median":-9.795122,"eighty":-4.333623,"marketCap":1087721785},{"date":"2023-05-12","current":-17.975574,"twenty":-18.548481,"median":-9.809491,"eighty":-4.342105,"marketCap":1227408161},{"date":"2023-05-19","current":-17.7789,"twenty":-18.385145,"median":-9.923908,"eighty":-4.345574,"marketCap":1213978850},{"date":"2023-05-26","current":-18.14807,"twenty":-18.548481,"median":-10.050322,"eighty":-4.359142,"marketCap":1239186528},{"date":"2023-06-02","current":-20.069433,"twenty":-18.624,"median":-10.097881,"eighty":-4.366759,"marketCap":1370381033},{"date":"2023-06-09","current":-21.42026,"twenty":-18.679679,"median":-10.133562,"eighty":-4.369631,"marketCap":1462618218},{"date":"2023-06-16","current":-20.925237,"twenty":-18.866911,"median":-10.16981,"eighty":-4.375728,"marketCap":1428817014},{"date":"2023-06-23","current":-21.134993,"twenty":-18.937913,"median":-10.21543,"eighty":-4.380543,"marketCap":1443139558},{"date":"2023-06-30","current":-19.937075,"twenty":-19.13128,"median":-10.25893,"eighty":-4.382308,"marketCap":1361343322},{"date":"2023-07-07","current":-19.327719,"twenty":-19.403716,"median":-10.300042,"eighty":-4.384874,"marketCap":1319735326},{"date":"2023-07-14","current":-19.516534,"twenty":-19.527631,"median":-10.366739,"eighty":-4.396081,"marketCap":1332627944},{"date":"2023-07-21","current":-18.778441,"twenty":-19.516534,"median":-10.433806,"eighty":-4.40569,"marketCap":1282229526},{"date":"2023-07-28","current":-18.083261,"twenty":-19.456456,"median":-10.472595,"eighty":-4.425522,"marketCap":1234761248},{"date":"2023-08-04","current":-18.684034,"twenty":-19.430709,"median":-10.508916,"eighty":-4.445846,"marketCap":1275783217},{"date":"2023-08-11","current":-19.793943,"twenty":-19.456456,"median":-10.529051,"eighty":-4.466169,"marketCap":1467760467},{"date":"2023-08-18","current":-19.297154,"twenty":-19.516534,"median":-10.56417,"eighty":-4.47125,"marketCap":1430922557},{"date":"2023-08-25","current":-21.788862,"twenty":-19.594416,"median":-10.725698,"eighty":-4.489816,"marketCap":1615687698},{"date":"2023-09-01","current":-22.790203,"twenty":-19.620281,"median":-10.783103,"eighty":-4.508424,"marketCap":1689939110},{"date":"2023-09-08","current":-21.773337,"twenty":-19.662379,"median":-10.81952,"eighty":-4.516812,"marketCap":1614536513},{"date":"2023-09-15","current":-22.891113,"twenty":-19.937195,"median":-10.874844,"eighty":-4.541754,"marketCap":1697421810},{"date":"2023-09-22","current":-21.88201,"twenty":-20.044607,"median":-10.927771,"eighty":-4.55153,"marketCap":1622594806},{"date":"2023-09-29","current":-20.640037,"twenty":-20.232827,"median":-10.973642,"eighty":-4.576935,"marketCap":1530500032},{"date":"2023-10-06","current":-20.546889,"twenty":-20.307025,"median":-10.998264,"eighty":-4.587214,"marketCap":1523592923},{"date":"2023-10-13","current":-21.191163,"twenty":-20.399581,"median":-11.044212,"eighty":-4.596272,"marketCap":1571367088},{"date":"2023-10-20","current":-20.127723,"twenty":-20.430908,"median":-11.063294,"eighty":-4.598275,"marketCap":1492510937},{"date":"2023-10-27","current":-22.829497,"twenty":-20.455558,"median":-11.08551,"eighty":-4.599291,"marketCap":1692852872},{"date":"2023-11-03","current":-25.350703,"twenty":-20.512907,"median":-11.133626,"eighty":-4.606404,"marketCap":1879805335},{"date":"2023-11-10","current":-18.349717,"twenty":-20.534125,"median":-11.159417,"eighty":-4.623679,"marketCap":1893819287},{"date":"2023-11-17","current":-18.699474,"twenty":-20.512907,"median":-11.219301,"eighty":-4.647268,"marketCap":1929916591},{"date":"2023-11-24","current":-19.986078,"twenty":-20.508077,"median":-11.235768,"eighty":-4.660326,"marketCap":2062703104},{"date":"2023-12-01","current":-19.642567,"twenty":-20.498333,"median":-11.326512,"eighty":-4.691605,"marketCap":2027250394},{"date":"2023-12-08","current":-19.523899,"twenty":-20.469266,"median":-11.343011,"eighty":-4.703566,"marketCap":2015003094},{"date":"2023-12-15","current":-21.372612,"twenty":-20.485729,"median":-11.403123,"eighty":-4.710056,"marketCap":2205803131},{"date":"2023-12-22","current":-21.178997,"twenty":-20.539127,"median":-11.433755,"eighty":-4.725299,"marketCap":2185820695},{"date":"2023-12-29","current":-22.378161,"twenty":-20.560916,"median":-11.460738,"eighty":-4.752445,"marketCap":2309582881},{"date":"2024-01-05","current":-21.616192,"twenty":-20.635863,"median":-11.478255,"eighty":-4.774704,"marketCap":2230942325},{"date":"2024-01-12","current":-24.694637,"twenty":-20.763319,"median":-11.573996,"eighty":-4.807425,"marketCap":2548659433},{"date":"2024-01-19","current":-28.378521,"twenty":-20.874895,"median":-11.672989,"eighty":-4.871722,"marketCap":2928862002},{"date":"2024-01-26","current":-30.347082,"twenty":-20.925237,"median":-11.754932,"eighty":-4.928537,"marketCap":3132031295},{"date":"2024-02-02","current":-31.796601,"twenty":-20.995241,"median":-11.84903,"eighty":-5.022175,"marketCap":3281631848},{"date":"2024-02-09","current":-31.989395,"twenty":-21.094154,"median":-11.907283,"eighty":-5.032659,"marketCap":3301529459},{"date":"2024-02-16","current":-33.160435,"twenty":-21.134993,"median":-12.008876,"eighty":-5.086047,"marketCap":3422389019},{"date":"2024-02-23","current":-29.405371,"twenty":-21.18143,"median":-12.106086,"eighty":-5.094177,"marketCap":3321660162},{"date":"2024-03-01","current":-29.504379,"twenty":-21.252364,"median":-12.196466,"eighty":-5.100274,"marketCap":3332844203},{"date":"2024-03-08","current":-29.854208,"twenty":-21.362618,"median":-12.275201,"eighty":-5.134457,"marketCap":3372361147},{"date":"2024-03-15","current":-29.570385,"twenty":-21.39159,"median":-12.312278,"eighty":-5.167912,"marketCap":3340300230},{"date":"2024-03-22","current":-30.118229,"twenty":-21.456111,"median":-12.35282,"eighty":-5.193104,"marketCap":3402185256},{"date":"2024-03-28","current":-28.586905,"twenty":-21.586005,"median":-12.411316,"eighty":-5.211962,"marketCap":3229205423},{"date":"2024-04-05","current":-27.326204,"twenty":-21.698819,"median":-12.663882,"eighty":-5.224529,"marketCap":3086795302},{"date":"2024-04-12","current":-28.685913,"twenty":-21.801282,"median":-12.695915,"eighty":-5.23565,"marketCap":3240389464},{"date":"2024-04-19","current":-24.831203,"twenty":-21.90599,"median":-12.746573,"eighty":-5.260951,"marketCap":2804957470},{"date":"2024-04-26","current":-25.561122,"twenty":-21.970513,"median":-12.778856,"eighty":-5.33492,"marketCap":2887409933},{"date":"2024-05-03","current":-27.460667,"twenty":-22.002271,"median":-12.852662,"eighty":-5.443511,"marketCap":3101984415},{"date":"2024-05-10","current":-23.864016,"twenty":-22.106629,"median":-13.01501,"eighty":-5.504053,"marketCap":3075904561},{"date":"2024-05-17","current":-24.386628,"twenty":-22.316456,"median":-13.122963,"eighty":-5.514677,"marketCap":3143265660},{"date":"2024-05-24","current":-22.578036,"twenty":-22.408348,"median":-13.19089,"eighty":-5.517064,"marketCap":2910150846},{"date":"2024-05-31","current":-21.016071,"twenty":-22.408348,"median":-13.405255,"eighty":-5.517064,"marketCap":2708824416},{"date":"2024-06-07","current":-23.270938,"twenty":-22.480222,"median":-13.492753,"eighty":-5.517064,"marketCap":2999461067},{"date":"2024-06-14","current":-22.859895,"twenty":-22.573944,"median":-13.658594,"eighty":-5.526194,"marketCap":2946480428},{"date":"2024-06-21","current":-21.297929,"twenty":-22.578036,"median":-13.849482,"eighty":-5.550065,"marketCap":2745153997},{"date":"2024-06-28","current":-20.18224,"twenty":-22.604654,"median":-14.065248,"eighty":-5.737455,"marketCap":2601349404},{"date":"2024-07-05","current":-19.548058,"twenty":-22.604654,"median":-14.207014,"eighty":-5.875249,"marketCap":2519607846},{"date":"2024-07-12","current":-25.833502,"twenty":-22.663386,"median":-14.56294,"eighty":-6.158782,"marketCap":3329757590},{"date":"2024-07-15","current":-26.081274,"twenty":-22.683944,"median":-14.611833,"eighty":-6.204137,"marketCap":3361693680},{"date":"2024-08-02","current":-27.685273,"twenty":-22.729538,"median":-15.101131,"eighty":-7.080248,"marketCap":3568437841},{"date":"2024-08-09","current":-20.650678,"twenty":-22.791755,"median":-15.174216,"eighty":-7.173892,"marketCap":3174814544},{"date":"2024-08-16","current":-20.941919,"twenty":-22.791755,"median":-15.356928,"eighty":-7.243187,"marketCap":3219589736},{"date":"2024-08-23","current":-21.062812,"twenty":-22.791755,"median":-15.420877,"eighty":-7.280035,"marketCap":3238175665},{"date":"2024-08-30","current":-21.524403,"twenty":-22.791755,"median":-15.493961,"eighty":-7.318659,"marketCap":3309140119},{"date":"2024-09-06","current":-20.53528,"twenty":-22.791755,"median":-15.548775,"eighty":-7.330832,"marketCap":3157073430},{"date":"2024-09-13","current":-19.842894,"twenty":-22.791755,"median":-15.658402,"eighty":-7.386643,"marketCap":3050626748},{"date":"2024-09-20","current":-19.386799,"twenty":-22.791755,"median":-15.731487,"eighty":-7.41883,"marketCap":2980507108},{"date":"2024-09-27","current":-16.76013,"twenty":-22.791755,"median":-15.7863,"eighty":-7.470507,"marketCap":2576685567},{"date":"2024-10-04","current":-16.073239,"twenty":-22.791755,"median":-15.877656,"eighty":-7.496684,"marketCap":2471083699},{"date":"2024-10-11","current":-16.595276,"twenty":-22.791755,"median":-15.923334,"eighty":-7.600254,"marketCap":2551341118},{"date":"2024-10-18","current":-16.864537,"twenty":-22.791755,"median":-15.959877,"eighty":-7.641123,"marketCap":2592737050},{"date":"2024-10-25","current":-16.045763,"twenty":-22.791755,"median":-16.042097,"eighty":-7.711567,"marketCap":2466859624},{"date":"2024-10-31","current":-16.188637,"twenty":-22.791755,"median":-16.087775,"eighty":-7.784511,"marketCap":2488824813},{"date":"2024-11-08","current":-14.552491,"twenty":-22.793308,"median":-16.087775,"eighty":-7.860776,"marketCap":2592089652},{"date":"2024-11-15","current":-14.300163,"twenty":-22.793308,"median":-16.087775,"eighty":-7.961667,"marketCap":2547145116},{"date":"2024-11-22","current":-12.907511,"twenty":-22.793308,"median":-16.087775,"eighty":-8.046396,"marketCap":2299085853},{"date":"2024-11-29","current":-13.276297,"twenty":-22.793308,"median":-16.087775,"eighty":-8.103024,"marketCap":2364774020},{"date":"2024-12-06","current":-12.795905,"twenty":-22.793308,"median":-16.087775,"eighty":-8.12743,"marketCap":2279206539},{"date":"2024-12-13","current":-12.50961,"twenty":-22.793308,"median":-16.087775,"eighty":-8.178203,"marketCap":2228211778},{"date":"2024-12-20","current":-12.029218,"twenty":-22.793308,"median":-16.087775,"eighty":-8.232893,"marketCap":2142644297},{"date":"2024-12-27","current":-12.54843,"twenty":-22.793308,"median":-16.087775,"eighty":-8.272654,"marketCap":2235126322},{"date":"2025-01-03","current":-12.208758,"twenty":-22.793308,"median":-16.087775,"eighty":-8.306032,"marketCap":2174624062},{"date":"2025-01-10","current":-12.058333,"twenty":-22.79486,"median":-16.087775,"eighty":-8.349042,"marketCap":2147830205},{"date":"2025-01-17","current":-11.024761,"twenty":-22.79486,"median":-16.087775,"eighty":-8.387198,"marketCap":1963730473},{"date":"2025-01-24","current":-11.301351,"twenty":-22.79486,"median":-16.087775,"eighty":-8.421336,"marketCap":2012996598},{"date":"2025-01-31","current":-11.587645,"twenty":-22.79486,"median":-16.087775,"eighty":-8.512709,"marketCap":2063991360},{"date":"2025-02-07","current":-11.626465,"twenty":-22.79486,"median":-16.087775,"eighty":-8.629402,"marketCap":2070905904},{"date":"2025-02-14","current":-6.537248,"twenty":-22.79486,"median":-16.087775,"eighty":-8.645873,"marketCap":1794324147},{"date":"2025-02-21","current":-6.930226,"twenty":-22.79486,"median":-16.087775,"eighty":-8.645873,"marketCap":1902187506},{"date":"2025-02-28","current":-6.455028,"twenty":-22.79486,"median":-16.087775,"eighty":-8.645873,"marketCap":1771756793},{"date":"2025-03-07","current":-6.081887,"twenty":-22.796413,"median":-16.087775,"eighty":-8.650599,"marketCap":1669338046},{"date":"2025-03-14","current":-6.046805,"twenty":-22.796413,"median":-16.087775,"eighty":-8.650599,"marketCap":1659708933},{"date":"2025-03-21","current":-5.880964,"twenty":-22.796413,"median":-16.087775,"eighty":-8.650599,"marketCap":1614189490},{"date":"2025-03-28","current":-5.558851,"twenty":-22.796413,"median":-16.087775,"eighty":-8.650599,"marketCap":1525776725},{"date":"2025-04-04","current":-4.965652,"twenty":-22.796413,"median":-16.087775,"eighty":-8.650599,"marketCap":1362957177},{"date":"2025-04-11","current":-5.029437,"twenty":-22.79486,"median":-16.087775,"eighty":-8.645873,"marketCap":1380464656},{"date":"2025-04-17","current":-5.160196,"twenty":-22.79486,"median":-16.087775,"eighty":-8.645873,"marketCap":1416354986},{"date":"2025-04-25","current":-6.081887,"twenty":-22.796413,"median":-16.087775,"eighty":-8.650599,"marketCap":1669338046},{"date":"2025-05-02","current":-6.528381,"twenty":-22.796413,"median":-16.087775,"eighty":-8.650599,"marketCap":1791890393},{"date":"2025-05-09","current":-5.185048,"twenty":-22.796413,"median":-16.087775,"eighty":-8.650599,"marketCap":1592240087},{"date":"2025-05-16","current":-4.936919,"twenty":-22.796413,"median":-16.087775,"eighty":-8.650599,"marketCap":1516043779},{"date":"2025-05-23","current":-5.327651,"twenty":-22.796413,"median":-16.087775,"eighty":-8.650599,"marketCap":1636031068},{"date":"2025-05-30","current":-5.718383,"twenty":-22.796413,"median":-16.087775,"eighty":-8.650599,"marketCap":1756018358},{"date":"2025-06-06","current":-6.01785,"twenty":-22.796413,"median":-16.087775,"eighty":-8.650599,"marketCap":1847979419},{"date":"2025-06-13","current":-6.354393,"twenty":-22.796413,"median":-16.087775,"eighty":-8.650599,"marketCap":1951326135},{"date":"2025-06-20","current":-6.234607,"twenty":-22.797965,"median":-16.087775,"eighty":-8.644345,"marketCap":1914541711},{"date":"2025-06-27","current":-6.357245,"twenty":-22.797965,"median":-16.087775,"eighty":-8.623821,"marketCap":1952201955},{"date":"2025-07-03","current":-6.303056,"twenty":-22.797965,"median":-16.087775,"eighty":-8.578381,"marketCap":1935561382},{"date":"2025-07-11","current":-6.5027,"twenty":-22.797965,"median":-16.087775,"eighty":-8.537547,"marketCap":1996868756},{"date":"2025-07-18","current":-6.300204,"twenty":-22.797965,"median":-16.087775,"eighty":-8.47506,"marketCap":1934685562},{"date":"2025-07-25","current":-7.081669,"twenty":-22.797965,"median":-16.087775,"eighty":-8.47506,"marketCap":2174660141},{"date":"2025-08-01","current":-6.94477,"twenty":-22.797965,"median":-16.087775,"eighty":-8.47506,"marketCap":2132620799},{"date":"2025-08-08","current":-5.919479,"twenty":-22.797965,"median":-16.087775,"eighty":-8.47506,"marketCap":1964095003},{"date":"2025-08-15","current":-6.437202,"twenty":-22.797965,"median":-16.087775,"eighty":-8.47506,"marketCap":2135876627}],"updateTime":1755544422699},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IDYA\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2537317942","title":"IDEAYA Biosciences Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2537317942","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537317942?lang=en_us&edition=fundamental","pubTime":"2025-05-22 21:54","pubTimestamp":1747922040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IDYA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 22, 2025 09:54 ET (13:54 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA"],"gpt_icon":0},{"id":"2533891928","title":"RBC Capital Reaffirms Their Buy Rating on IDEAYA Biosciences (IDYA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2533891928","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533891928?lang=en_us&edition=fundamental","pubTime":"2025-05-08 09:57","pubTimestamp":1746669472,"startTime":"0","endTime":"0","summary":"In a report released on May 6, Gregory Renza from RBC Capital maintained a Buy rating on IDEAYA Biosciences (IDYA – Research Report), with a price ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-reaffirms-their-buy-rating-on-ideaya-biosciences-idya-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-reaffirms-their-buy-rating-on-ideaya-biosciences-idya-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDYA"],"gpt_icon":0},{"id":"2533658457","title":"IDEAYA Gets FDA Clearance to Initiate Clinical Trial of Antibody Drug Conjugate Program in Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2533658457","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533658457?lang=en_us&edition=fundamental","pubTime":"2025-05-06 22:23","pubTimestamp":1746541393,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences  said Tuesday that the US Food and Drug Administration has accepted an investigational new drug application for the initiation of a phase 1 clinical trial to evaluate IDE849 , a potential delta-like ligand 3-targeting topo-I-payload antibody drug conjugate program in solid tumors.The DLL3 is upregulated in solid tumor types, including small cell lung cancer, neuroendocrine tumors, non-small cell lung cancer and melanoma, among other solid tumors, the company's president and chief executive officer Yujiro Hata said.IDE849, which is in an ongoing multi-site open label phase 1 clinical trial for advanced solid tumors by Jiangsu Hengrui Pharmaceuticals, has reached therapeutic dose levels, the company said.As of the data cut-off date Dec. 10, 2024, treatment related adverse events were predominantly grade 1 or 2, and the phase 1 dose escalation is ongoing with no reported drug-related discontinuations, and the maximum tolerated dose has not yet been reached. Jiangsu Heng","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","IDYA"],"gpt_icon":0},{"id":"2533634226","title":"IDEAYA Biosciences Posts Q1 Net Loss; Cash Runway Extended Through 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2533634226","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533634226?lang=en_us&edition=fundamental","pubTime":"2025-05-06 21:40","pubTimestamp":1746538826,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences  reported a Q1 net loss Tuesday of $0.82 per diluted share.Analysts polled by FactSet expected a loss of $0.66.As expected, no revenue for the quarter ended March 31 was reported.As of March 31, the company said it had $1.05 billion in cash and/or cash equivalents on hand, and expects it could be sufficient to fund operations through 2029.The company's shares were up 1.7% in recent premarket activity on Tuesday.Price: 20.83, Change: +0.36, Percent Change: +1.73","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IDYA","BK4139"],"gpt_icon":0},{"id":"2533689704","title":"IDEAYA Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2533689704","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533689704?lang=en_us&edition=fundamental","pubTime":"2025-05-06 19:23","pubTimestamp":1746530608,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences Inc reports results for the quarter ended March 31 - Earnings SummaryIDEAYA Biosciences Inc IDYA.OQ reported a quarterly adjusted loss of 82 cents per share for the quarter ended Ma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nL8N3RE112:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA"],"gpt_icon":0},{"id":"2533837056","title":"BRIEF-IDEAYA Biosciences Announces US FDA IND-Clearance For IDE849, A Potential First-In-Class DLL3 TOP1 ADC, For A Phase 1 Study In Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2533837056","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533837056?lang=en_us&edition=fundamental","pubTime":"2025-05-06 18:51","pubTimestamp":1746528673,"startTime":"0","endTime":"0","summary":"BRIEF-IDEAYA Biosciences Announces US FDA IND-Clearance For IDE849, A Potential First-In-Class DLL3 TOP1 ADC, For A Phase 1 Study In Solid TumorsMay 6 (Reuters) - IDEAYA Biosciences Inc IDYA.O:IDEAYA ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nTUABXS7JJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"gpt_icon":0},{"id":"2533888476","title":"IDEAYA Biosciences Q1 EPS $(0.82) Misses $(0.67) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2533888476","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533888476?lang=en_us&edition=fundamental","pubTime":"2025-05-06 18:35","pubTimestamp":1746527754,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(0.82) per share which missed the analyst consensus estimate of $(0.67) by 22.39 percent. This is a 54.72 percent decrease over losses of $(0.53) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45216441/ideaya-biosciences-q1-eps-0-82-misses-0-67-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA"],"gpt_icon":0},{"id":"2533507521","title":"Earnings Flash (IDYA) IDEAYA Biosciences Posts Q1 Net Loss $0.82, vs. FactSet Est of $0.66 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2533507521","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533507521?lang=en_us&edition=fundamental","pubTime":"2025-05-06 18:21","pubTimestamp":1746526872,"startTime":"0","endTime":"0","summary":"Earnings Flash (IDYA) IDEAYA Biosciences Posts Q1 Net Loss $0.82, vs. FactSet Est of $0.66 Loss","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IDYA"],"gpt_icon":0},{"id":"2533507588","title":"IDEAYA Biosciences Reports Q1 2025 Results: Net Loss Down to $72.2M, Increased G&A Expenses Amid Pipeline Support","url":"https://stock-news.laohu8.com/highlight/detail?id=2533507588","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533507588?lang=en_us&edition=fundamental","pubTime":"2025-05-06 18:06","pubTimestamp":1746525997,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire  on May 06, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nNDL4RB5nc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDYA"],"gpt_icon":0},{"id":"2533950493","title":"Press Release: IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2533950493","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533950493?lang=en_us&edition=fundamental","pubTime":"2025-05-06 18:05","pubTimestamp":1746525900,"startTime":"0","endTime":"0","summary":"-- $1.05 billion of cash, cash equivalents and marketable securities as of. March 31, 2025, and an updated cash runway guidance into 2029; commercial. -- Over 300 patients enrolled in darovasertib and crizotinib registrational. 1L HLA-A2-negative MUM trial; targeting median PFS results by YE 2025 to. -- Successful FDA Type D meeting completed to finalize darovasertib Ph3. registrational trial design and received U.S. FDA Breakthrough Therapy. -- Targeting three darovasertib program clinical data updates at medical. conferences in 2025, including 1L MUM mOS results in >40 patients and. targeting clinical data update in over 40 SCLC patients at a medical. SOUTH SAN FRANCISCO, Calif., May 6, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the first quarter that ended March 31, 2025.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","PFS","BK4097","BK4022","BK4195","BK4211","R","OS","BK4080","BK4139","PB","BK4232","BK4231","IDYA"],"gpt_icon":0},{"id":"2530478869","title":"IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2530478869","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530478869?lang=en_us&edition=fundamental","pubTime":"2025-04-28 18:00","pubTimestamp":1745834400,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., April 28, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events.Barclays Hosted: Peter Lawson's Catalyst & Key Debate Calls & Investor 1x1'sThursday, May 8th, 2025 at 11:00 AM ET. Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Peter Lawson, D.Phil., Managing Director, Equity Research Analyst. 2025 RBC Capital Markets Global Healthcare ConferenceTuesday, May 20th, 2025 at 8:30 AM ET. Fireside chat with Yujiro S. Hata, President and Chief Executive Officer hosted by Gregory Renza, M.D., Director and Senior Biotechnology Research Analyst. IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/ideaya-biosciences-participate-upcoming-may-100000236.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ideaya-biosciences-participate-upcoming-may-100000236.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IDYA"],"gpt_icon":0},{"id":"2530907360","title":"BRIEF-Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2530907360","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530907360?lang=en_us&edition=fundamental","pubTime":"2025-04-25 18:21","pubTimestamp":1745576471,"startTime":"0","endTime":"0","summary":"BRIEF-Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)April 25 (Reuters) - IDEAYA Biosciences Inc IDYA.O:IDEAYA BIOSCIENCES ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)Source text: ID:nPn8WlFDpaFurther company coverage: IDYA.O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nTUA26ZJQF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"gpt_icon":0},{"id":"2530181572","title":"IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2530181572","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530181572?lang=en_us&edition=fundamental","pubTime":"2025-04-25 18:00","pubTimestamp":1745575200,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., April 25, 2025 /PRNewswire/ --IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 24, 2025, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 185,400 shares of the Company's common stock to four newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan  as an inducement material to such individuals' entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635.The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635.Investor and Med","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/ideaya-biosciences-announces-inducement-grants-100000152.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ideaya-biosciences-announces-inducement-grants-100000152.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TQQQ","MNQmain","LU2210150020.SGD","PSQ","QID","NDAQ",".IXIC","IE00B64PRP62.GBP","SQQQ","USJW.SI","IE00BKPKM429.USD","NQmain","BK4112","IE00B3QW5Z07.USD","BK4588","QLD","LU2095319765.USD","IE00BGHQF748.EUR","USAW.SI","BK4585","IDYA","LU2210149790.SGD","TSYW.SI","BK4139","NVIW.SI"],"gpt_icon":1},{"id":"2527256853","title":"IDEAYA Biosciences’ Trial Expansion and Regulatory Uncertainties Lead to Hold Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2527256853","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527256853?lang=en_us&edition=fundamental","pubTime":"2025-04-16 15:35","pubTimestamp":1744788939,"startTime":"0","endTime":"0","summary":"Andrew Berens, an analyst from Leerink Partners, maintained the Hold rating on IDEAYA Biosciences (IDYA – Research Report). The associated price ta...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/ideaya-biosciences-trial-expansion-and-regulatory-uncertainties-lead-to-hold-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/ideaya-biosciences-trial-expansion-and-regulatory-uncertainties-lead-to-hold-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDYA"],"gpt_icon":0},{"id":"2527498492","title":"Mizuho Securities Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2527498492","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527498492?lang=en_us&edition=fundamental","pubTime":"2025-04-15 18:17","pubTimestamp":1744712278,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on IDEAYA Biosciences (IDYA – Research Report) today and set a price target of ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-its-buy-rating-for-ideaya-biosciences-idya?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-its-buy-rating-for-ideaya-biosciences-idya?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MFG","IDYA"],"gpt_icon":0},{"id":"2527190981","title":"Ideaya trial design consisent with guidance, says Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2527190981","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527190981?lang=en_us&edition=fundamental","pubTime":"2025-04-14 23:50","pubTimestamp":1744645832,"startTime":"0","endTime":"0","summary":"Oppenheimer reiterates an Outperform rating on Ideaya Biosciences (IDYA) with a $40 price target after the company announced that it met with the F...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ideaya-trial-design-consisent-with-guidance-says-oppenheimer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ideaya-trial-design-consisent-with-guidance-says-oppenheimer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","IDYA","BK4139","OPY"],"gpt_icon":0},{"id":"2527716165","title":"Ideaya Biosciences Completes Phase 3 Trial Design Meetings With FDA; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2527716165","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527716165?lang=en_us&edition=fundamental","pubTime":"2025-04-14 21:28","pubTimestamp":1744637300,"startTime":"0","endTime":"0","summary":"Ideaya Biosciences  said Monday it has successfully completed a Type D meeting with the US Food and Drug Administration on the design of a phase 3 registrational trial to evaluate the safety and efficacy of its darovasertib precision oncology candidate to treat primary uveal melanoma.The trial is expected to start in H1 and will use eye preservation and the proportion of patients with vision loss as its primary endpoints and with no detriment to event-free-survival as a secondary endpoint for both cohorts, the oncology company said.Other secondary endpoints will include overall response rate, the proportion of patients with clinically significant macular edema and the proportion of subjects with legal blindness.Shares were almost 6% higher in recent premarket activity.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","IDYA"],"gpt_icon":0},{"id":"2527074135","title":"BRIEF-Ideaya Biosciences Announces Successful FDA Type D Meeting for Darovasertib","url":"https://stock-news.laohu8.com/highlight/detail?id=2527074135","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527074135?lang=en_us&edition=fundamental","pubTime":"2025-04-14 18:08","pubTimestamp":1744625297,"startTime":"0","endTime":"0","summary":"BRIEF-Ideaya Biosciences Announces Successful FDA Type D Meeting for DarovasertibApril 14 (Reuters) - IDEAYA Biosciences Inc IDYA.O:IDEAYA BIOSCIENCES ANNOUNCES SUCCESSFUL FDA TYPE D MEETING ON PHASE ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250414:nFWN3QQ077:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"gpt_icon":0},{"id":"2527158632","title":"IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2527158632","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527158632?lang=en_us&edition=fundamental","pubTime":"2025-04-14 18:00","pubTimestamp":1744624800,"startTime":"0","endTime":"0","summary":"Targeting to initiate Phase 3 randomized registrational trial for darovasertib in the neoadjuvant setting in primary UM in H1 2025. Clinical endpoints supportive of full approval based on FDA Type D Meeting: Eye preservation rate as the primary endpoint for enucleation patients. Proportion of patients with best corrected visual acuity 15-letter loss from time of randomization and time of completion of plaque brachytherapy  as the primary endpoint for PB patients. No detriment to Event-Free-Survival  is required for both cohorts as a secondary endpoint. We project registrational trial enrollment for the enucleation cohort will be 120 patients and 400 patients for the plaque brachytherapy cohort with a 2:1 randomization. Potential to submit the enucleation cohort data for regulatory review earlier than the PB cohort pending the EFS data maturity in both cohorts. FDA Guidance from the Type D Meeting on the Phase 3 Neoadjuvant Darovasertib Registrational Trial Design for Potential Regulato","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/ideaya-biosciences-announces-successful-fda-100000977.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ideaya-biosciences-announces-successful-fda-100000977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4211","PB","BK4139","IDYA"],"gpt_icon":0},{"id":"2526955292","title":"Ideaya Biosciences Begins Phase 1/2 Expansion in Urothelial Cancer Treatment Trial in Combination With Gilead's Trodelvy","url":"https://stock-news.laohu8.com/highlight/detail?id=2526955292","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526955292?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:18","pubTimestamp":1744283886,"startTime":"0","endTime":"0","summary":"Ideaya Biosciences (IDYA) said Thursday it launched a phase 1/2 expansion in a clinical trial of its experimental IDE397 treatment in combination with Gilead Sciences' (GILD) Trodelvy in methylthioade","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BKVL7J92.USD","LU0109394709.USD","IE00B19Z3581.USD","LU1571399168.USD","LU1430594728.SGD","LU0320765992.SGD","BK4578","LU0889565916.HKD","LU2089984988.USD","BK4566","IDYA","IE00B19Z3B42.SGD","LU1066051498.USD","LU2468319806.SGD","IE00B7SZLL34.SGD","GILD","LU0234570918.USD","LU0289739699.SGD","LU1066053197.SGD","LU0058720904.USD","BK4532","BK4588","BK4550","LU2087621335.USD","IE00BSNM7G36.USD","LU1839511570.USD","BK4583","LU1585245621.USD","BK4568","BK4139","IE00BZ1G4Q59.USD","IE00B3T34201.USD","IE0002270589.USD","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":86,"code":"91000000","status":"200"}]}}